Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Zika virus kills brain cancer cells - study
The Zika virus, which is spread my mosquitoes, causes serious birth defects.
Findings may be used to treat fatal disease 

A study by US researchers has revealed that Zika virus can kill brain cancer stem cells - the type of cells that are most resistant to standard treatment.

Their findings, published in the Journal of Experimental Medicine, suggest that Zika virus - which causes serious birth defects in humans - could be directed at malignant cells in the brain.

Researchers say their findings have the potential to improve people’s chances against glioblastoma - the most common form of primary brain tumour in adults.

“We showed that Zika virus can kill the kind of glioblastoma cells that tend to be resistant to current treatments and lead to death,” explained co-author Michael Diamond, a professor of Medicine at Washington University School of Medicine.

In the study, researchers from Washington University School of Medicine and the University of California San Diego School of Medicine assessed if the virus could kill stem cells in glioblastomas removed from patients at diagnosis.

Their findings suggest that Zika infection and chemotherapy/radiotherapy compliment each other. While the standard treatment kills the majority of the tumour cells but often leads the stem cells intact, Zika virus attacks the stem cells but bypasses the greater part of the tumour.

“We see Zika one day being used in combination with current therapies to eradicate the whole tumour,” said Chheda, an assistant professor of medicine and neurology.

To see if Zika could be used to treat cancer in a living animal, the researchers injected either Zika virus or salt water (a placebo) into the brain tumours of mice. They found that tumours were markedly smaller in the Zika treated mice two weeks after injection, and those mice survived much longer than the ones injected with salt water.

Researchers say that if Zika virus was to be used in humans, it would have to be injected straight into the brain. If injected anywhere else in the body, the immune system would destroy it before it reaches the brain.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.